Helicobacter Pylori Infection and Gastric Disease in Bhutan: First Community-Wide, Population-Based Study

NACompletedINTERVENTIONAL
Enrollment

1,043

Participants

Timeline

Start Date

December 5, 2019

Primary Completion Date

December 11, 2020

Study Completion Date

March 21, 2023

Conditions
H.PyloriGastric CancerH Pylori Eradication
Interventions
DRUG

Rabeprazole Sodium, Amoxicillin Hydrate, Clarithromycin

7 days therapy

DIAGNOSTIC_TEST

Upper gastrointestinal endoscopy for the H. pylori and serum pepsinogen positive individuals (high risk group of gastric cancer)

Endoscopic examinations were conducted using a GIF-150 endoscope in combination with the CV150 system (Olympus Co., Tokyo, Japan).

DEVICE

Urea Breath Test for the prevalence of H pylori

After eradication of the H pylori with drug success of the therapy was assessed 6 to 8 weeks after treatment using the UBT(C13 Urea Breath Test: Beijing Richen-Force Science \& Techinology Co. Ltd.)

Trial Locations (1)

Unknown

Khesar Gyalpo University of Medical Sciences of Bhutan, Thimphu

All Listed Sponsors
collaborator

Oita University

OTHER

collaborator

Japan International Cooperation Agency

OTHER

collaborator

JDWNRH

OTHER

collaborator

Khesar Gyalpo University of Medical Sciences of Bhutan

UNKNOWN

collaborator

Royal Centre for Disease Control Bhutan

UNKNOWN

lead

Zero Helicobacter IGAN Network

OTHER

NCT07211880 - Helicobacter Pylori Infection and Gastric Disease in Bhutan: First Community-Wide, Population-Based Study | Biotech Hunter | Biotech Hunter